Tag Archives: Avtar Dhillon

Emerald Health Northern Vine Labs

Emerald Health Therapeutics Receives $26.5 Million from Exercise of Warrants and Triggers Acceleration of 721,700 Remaining $2.00 Warrants

Emerald Health Therapeutics Receives $26.5 Million from Exercise of Warrants and Triggers Acceleration of 721,700 Remaining $2.00 Warrants

VICTORIA, British Columbia, Dec. 21, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) has elected to exercise its right to accelerate the exercise of $2.00 common share purchase warrants (“Warrants”) issued by the Company on February 10, 2017.

Emerald Health Northern Vine Labs

Northern Vine Labs Expands Dealer’s License with Health Canada

VICTORIA, British Columbia, Dec. 15, 2017 /Weed Wire/ — Northern Vine Labs (“Company”), a subsidiary of Emerald Health Therapeutics Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) and Abattis Bioceuticals Corp. (“Abattis”) (CSE: ATT; OTC: ATTBF), today announced that Health Canada has approved an amendment to the Company’s dealer’s license.

Emerald Health Northern Vine Labs

Emerald Health Therapeutics Announces Positive Health Canada Review of License Application for Prominent Fouth Facility

VICTORIA, British Columbia, Nov. 28, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) announced today that its licensed producer application (submitted through its subsidiary, Emerald Health Botanicals) for its new Richmond, BC greenhouse facility under Access to Cannabis for Medical Purpose Regulations (“ACMPR”) has met the requirements of the paper-based review of Health Canada’s Office of Medical Cannabis (“OMC”).

Emerald Health Northern Vine Labs

Emerald Health Therapeutics Completes Investment in Licensed Dealer Northern Vine

VICTORIA, British Columbia, Nov. 21, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced today that it has completed its previously announced investment of $2.5 million into Northern Vine Canada Inc. (“Northern Vine”) to acquire 53% of the company and appoint three of its four directors.

Emerald Health Northern Vine Labs

Emerald Health Therapeutics Announces Positive Health Canada Review of its Licensed Producer Application for Pure Sunfarms Facility

RICHMOND, British Columbia, Nov. 15, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (TSXV: EMH; OTCQX: EMHTF) announced today that its licensed producer application for the Pure Sunfarms Delta 3 greenhouse facility under Access to Cannabis for Medical Purpose Regulations (“ACMPR”) has met the requirements of the paper-based review of Health Canada’s Office of Medical Cannabis (”OMC”).

Emerald Health Northern Vine Labs

Emerald Health Therapeutics to Acquire Control of Licensed Dealer Northern Vine

VICTORIA, British Columbia, Oct. 26, 2017 /Weed Wire/ – Emerald Health Therapeutics Inc. (“Emerald”) (EMH.V) (EMHTF) announced today that it has signed a definitive agreement (the “Agreement”) with Northern Vine Canada Inc. (“Northern Vine”) and Abattis Bioceuticals Corp. (“Abattis”) (CSE:ATT) (ATTBF) to invest $2.5 million into Northern Vine to acquire 53% of the company and appoint three of its four directors. Abattis will continue to hold the remaining 47% of Northern Vine.


Top